GLP-1 Weight Loss Plateau: Why You Stop Losing Weight and What to Do
Weight loss on a GLP-1 medication can be significant, but it is rarely linear. Many people experience rapid or steady progress initially, followed by a period when the number on the scale barely changes. This is often referred to as a GLP-1 weight loss plateau.
A plateau can be frustrating, particularly when a medication such as semaglutide or tirzepatide initially seemed to be working well. However, slower weight loss does not automatically mean the medication has stopped working. Weight loss generally slows over time with almost every intervention, including medication-based treatment.
In this blog, we understand why weight loss can stall on GLP-1 medications, how to tell whether you have reached a true plateau, and what to do next.
Why am I not losing weight on GLP-1?
A weight loss plateau is a period when your weight stops decreasing despite ongoing efforts to lose weight. However, a few days or even a week without a lower number on the scale does not necessarily mean you have reached a plateau.
Body weight can fluctuate for several reasons, including:
- Changes in fluid balance
- Higher sodium intake
- Constipation
- Menstrual cycle-related fluid retention
- Changes in physical activity
For this reason, looking at your overall weight trend is generally more useful than focusing on individual weigh-ins.
In the SURMOUNT clinical trial analysis, researchers defined a plateau as less than 5% additional weight change over a 12-week period and subsequent 12-week intervals. That definition was created for research and should not be used as a strict rule for every individual taking a GLP-1 medication.
Why Does Weight Loss Slow Down on GLP-1 Medications?
A slower rate of weight loss over time is a common biological pattern.
As body weight decreases, the body requires less energy to support its new size. This means the calorie deficit that contributed to weight loss earlier in treatment may gradually become smaller. At the same time, the body’s biological systems can respond to weight loss in ways that favour the recovery of lost weight.
GLP-1-based medications can help address some of these challenges by reducing appetite and improving satiety. Tirzepatide also acts on GIP receptors in addition to GLP-1 receptors. However, medication does not mean weight will continue falling indefinitely at the same rate.
Research modelling weight loss with dietary intervention, semaglutide, tirzepatide, and bariatric surgery has similarly found that weight loss eventually slows and approaches a plateau. The difference is that more effective interventions can change how much weight is lost and how long active weight loss continues before that plateau is reached.
6 Reasons You May Have Stopped Losing Weight on GLP-1
1. You May Still Be in the Dose-Escalation Phase
One possible reason for not losing weight on GLP-1 treatment is that you are still early in the treatment process.
Medications such as semaglutide and tirzepatide are generally started at lower doses and increased gradually according to their approved prescribing schedules and individual tolerability. The early doses are often part of a gradual dose-escalation process rather than the dose used for long-term treatment.
Weight-loss response can therefore differ substantially during the first few months.
This is also supported by a post-hoc analysis of SURMOUNT-1 that looked at people who had not achieved at least 5% weight loss by week 12. Of those categorised as late responders, 70% had achieved at least 5% weight loss by week 24 and 90% had done so by week 72.
A slower early response and a true long-term plateau are therefore not the same thing.
Do not increase your dose independently because you feel your weight loss has slowed. Questions about dose escalation, treatment response, and medication changes should be discussed with the clinician managing your treatment.
2. Your Weight Loss May Have Reached a Natural Plateau
Weight loss does not usually continue at the same speed throughout treatment.
The SURMOUNT-1 analysis provides useful insight into this pattern with tirzepatide. Participants with overweight had a median time to plateau of 24.3 weeks. For participants with class I obesity, it was 26 weeks, while participants with class II and class III obesity reached the median plateau point at 36.1 weeks.
By week 72, approximately 88% to 90% of participants across these BMI categories had reached the study’s definition of a plateau.
Individual weight-loss patterns can vary considerably. Still, the findings reinforce an important point: a weight plateau can be an expected part of long-term weight management with medication.
Higher doses of tirzepatide, younger age, and female sex were associated with a longer time before reaching a plateau in this analysis.
3. Your Calorie Needs Have Changed as You Lost Weight
Your body at 75 kg does not require exactly the same amount of energy as your body at 95 kg.
As weight decreases, energy expenditure generally decreases as well. The amount of food that created a meaningful calorie deficit at a higher weight may create a smaller deficit after substantial weight loss.
GLP-1 medications can significantly reduce appetite, and some people may struggle to eat enough to meet their nutritional needs. Extremely restrictive eating can also make it more difficult to consume adequate protein, fibre and other essential nutrients.
A plateau is therefore a good point to review the overall quality and pattern of your diet. Depending on your individual circumstances, this may include looking at:
- Whether your meals provide adequate protein
- Whether you are eating enough nutrient-dense foods
- How much of your intake comes from highly processed, energy-dense foods
- Whether appetite suppression is causing you to skip meals unintentionally
A registered dietitian can help assess these factors in the context of your weight, health conditions, and treatment plan.
4. Low Protein Intake and Changes in Lean Mass
When weight is lost, the body does not lose fat mass alone. Some lean mass can also be lost.
In a DXA substudy of SURMOUNT-1, participants treated with tirzepatide lost an average of 21.3% of their body weight over 72 weeks. Approximately 74% of the weight lost was fat mass and 26% was lean mass.
This does not mean tirzepatide specifically causes a quarter of every person’s weight loss to come from muscle. The study measured changes in a particular group of trial participants, and lean mass is not identical to skeletal muscle alone.
However, preserving lean tissue is an important consideration during significant weight loss.
Adequate protein intake, along with appropriate physical activity, particularly resistance training where medically suitable, can be part of a broader strategy to support body composition during weight loss.
Protein needs vary based on factors such as body weight, age, activity level, kidney function, and overall health. A personalised recommendation is more appropriate than applying one number to everyone taking a GLP-1 medication.
5. Changes in Physical Activity Can Affect Your Progress
GLP-1 medications can reduce appetite, but they do not replace the role of physical activity.
Regular movement contributes to overall energy expenditure and has benefits for cardiovascular health, physical function and metabolic health. Resistance training can also be particularly valuable during weight loss because maintaining muscle strength and lean tissue is an important consideration.
A plateau can be a useful time to review whether activity levels have changed.
The right exercise plan depends on your current fitness level, injuries, health conditions and treatment goals. More exercise is not always better, particularly when someone is struggling with poor nutritional intake or significant fatigue.
The focus should be on building a sustainable routine rather than trying to force the scale to move through excessive exercise.
6. The Scale May Be Hiding Short-Term Changes
A common concern is: “I am doing everything right, but the scale is not moving on GLP-1.” Short-term weight measurements can be misleading.
A person can retain more water temporarily after a high-sodium meal. Constipation can affect scale weight. Menstrual cycle-related changes can also cause short-term fluctuations. Changes in carbohydrate intake can alter glycogen stores, which are stored with water.
Looking at your weight trend over several weeks can give a clearer picture of whether weight loss has genuinely stalled. Other measures may also provide useful context, including:
- Waist circumference
- Changes in physical strength
- Body composition measurements
A plateau on the scale and a complete absence of physical change are not necessarily the same thing.
How Long Does a GLP-1 Weight Loss Plateau Last?
Some people experience a temporary period where weight loss slows before losing more weight. Others may eventually reach a longer-term period of weight stability.
The 2025 SURMOUNT analysis found median times to plateau ranging from 24.3 to 36.1 weeks in different BMI categories among tirzepatide-treated participants. But these numbers should not be treated as a personal deadline. The study used a specific definition of plateau, involved selected trial participants, and evaluated tirzepatide rather than every GLP-1 medication.
The timing of a semaglutide weight loss plateau or tirzepatide weight loss plateau can be influenced by several factors, including:
- Starting body weight
- Medication and dose
- Duration of treatment
- Individual response
- Diet and activity patterns
- Other health factors
A few stagnant weigh-ins are very different from a sustained plateau over many weeks. Looking at the bigger picture is essential before deciding that your medication has stopped working.
What to Do When Weight Loss Stalls on GLP-1
Look at the trend, not one number
Track weight consistently enough to identify longer-term patterns. Day-to-day fluctuations can hide the overall direction of change.
Check where you are in treatment
Someone still going through dose escalation may have a different weight-loss pattern from someone who has been on a stable maintenance dose for several months. Review your treatment timeline with your clinician rather than comparing your progress with someone else’s.
Reassess your nutrition
A plateau is a useful opportunity to look at what you are actually eating. Prioritising nutritionally balanced meals can become particularly important when appetite is significantly reduced.
Pay attention to protein intake and overall dietary quality, especially if you have been skipping meals because you rarely feel hungry.
Include regular movement and resistance training
Physical activity supports overall health during weight loss, while resistance training can help support muscle strength and lean tissue. Choose an approach that is appropriate for your fitness level and health status.
Do not change your medication dose on your own
If you are concerned that semaglutide, tirzepatide or another GLP-1-based medication has stopped working, speak with your prescribing clinician. They can assess your progress in the context of your treatment goals and determine whether any changes are appropriate.
When Should You Speak to Your Doctor About a GLP-1 Weight Loss Plateau?
Speak with your prescribing clinician if you are concerned about a sustained lack of progress, particularly if you have been following your prescribed treatment plan for an adequate period and your weight trend has remained unchanged.
You should also seek medical advice if you are experiencing:
- Persistent or severe side effects
- Difficulty eating enough to meet your nutritional needs
- Significant weakness or fatigue
- Concerns about medication administration or missed doses
- Unexpected weight changes
- Questions about changing your dose or stopping treatment
A clinician can assess whether your current treatment remains appropriate and whether other factors need attention.
When Medical Weight Loss Support Can Help
If your weight loss has stalled, it may be worth taking a closer look at your overall treatment plan. Factors such as your medication, nutrition, activity levels and underlying health can all influence your progress.
At ezweight, medical weight loss combines personalised assessment with expert guidance to help you take a more informed approach to long-term weight management.
Explore ezweight’s personalised medical weight loss support here.
Conclusion
Weight loss with GLP-1-based treatment is rarely a straight line. Clinical research shows that the rate of weight loss generally slows over time and that many people eventually reach a plateau.
What matters is the broader pattern. A temporary fluctuation, a slower rate of loss, and long-term weight stability can look similar on the scale while representing different stages of treatment.
Frequently Asked Questions (FAQs)
- How do I know if I have a real weight loss plateau on GLP-1?
A few days or a week without weight loss may simply reflect normal fluctuations. A longer-term trend provides a better picture of whether your progress has genuinely stalled.
- Can you still lose inches during a GLP-1 weight loss plateau?
Yes. Changes in body composition or body measurements may not always be reflected immediately on the scale.
- Should I eat less to break a weight loss plateau on GLP-1?
Not necessarily. Severely restricting food intake may make it harder to meet your nutritional needs. Review your overall diet with a healthcare professional rather than making drastic changes on your own.
- Should I increase my GLP-1 dose if my weight loss stops?
Do not change your dose without medical guidance. Your prescribing clinician can assess your treatment response and determine whether any adjustment is appropriate.
- Can I hit a weight loss plateau before reaching my goal weight?
Yes. A plateau can occur before you reach your personal goal weight, as weight loss does not usually continue at the same rate throughout treatment.
- Does exercise help with a GLP-1 weight loss plateau?
Regular physical activity can support overall health and weight management. Resistance training may also help support muscle strength and lean tissue during weight loss.
References
- Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity. 2025. https://onlinelibrary.wiley.com/doi/10.1111/cob.12734
- Hall KD. Body weight and fat mass dynamics with weight-loss interventions including semaglutide and tirzepatide. Research modelling the time course of weight loss and plateaus. https://onlinelibrary.wiley.com/doi/full/10.1002/oby.24027
- Post-hoc analysis of early and late weight-loss response in the SURMOUNT-1 trial. https://www.sciencedirect.com/science/article/pii/S2667368126000045
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16275